|
|
 |
|
Viewing report
|
|
|
|
ARYx Therapeutics (ARYX) - Financial and Strategic SWOT Analysis Review
GlobalData, Sep 2011, Pages: 40
ARYx Therapeutics (ARYX) - Financial and Strategic SWOT Analysis Review
Summary
ARYx Therapeutics, Inc. (ARYx) is a biopharmaceutical company principally engaged in the discovery and development of safer novel therapies for chronic oral markets. The company uses RetroMetabolic Drug Design technology to design structurally unique molecules. The company's product pipeline includes Tecarfarin(ATI-5923), Budiodarone(ATI-2042), Naronapride(ATI-7505), ATI-9242, ATI-20000 and ATI-24000. It products in clinical development are tecarfarin, an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots; budiodarone, an oral anti-arrhythmic agent for the treatment of atrial fibrillation; ATI-7505, a prokinetic agent for the treatment of various gastrointestinal disorders and ATI-9242, an agent for the treatment of schizophrenia and other psychiatric disorders. It mainly operates in the United States and United Kingdom. The company is headquartered in California, the US.
ARYx Therapeutics Key Recent Developments
Mar 09, 2011: FDA Informs Additional Delay On Phase III Development Of ARYx's Product Naronapride
Dec 21, 2010: ARYx Therapeutics To Transfer To NASDAQ Capital Market
Nov 15, 2010: ARYx Therapeutics Reports Net Loss Of $2.5 Million For Q3 2010
Oct 08, 2010: ARYx Therapeutics Receives NASDAQ Notice Of Non-Compliance
Jun 02, 2010: ARYx Announces Resignation Of Peter Milner, President Research And Development
This comprehensive SWOT profile of ARYx Therapeutics provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Customers who bought this item also bought
Nile Therapeutics, Inc. (NLTX) - Financial and Strategic SWOT Analysis Review
Echo Therapeutics, Inc. (ECTE) - Financial and Strategic SWOT Analysis Review
Arisyn Therapeutics Inc. - Product Pipeline Review - Q4 2010
Arisyn Therapeutics Inc. - Product Pipeline Review - Q4 2010
Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT Analysis Review
BioCryst Pharmaceuticals, Inc. (BCRX) - Financial and Strategic SWOT Analysis Review
Avexa Limited (AVX) - Financial and Strategic SWOT Analysis Review
Ironwood Pharmaceuticals, Inc. (IRWD) - Financial and Strategic SWOT Analysis Review
Azaya Therapeutics, Inc. - Product Pipeline Review - Q4 2010
Molecular Insight Pharmaceuticals, Inc. (MIPI) - Financial and Strategic SWOT Analysis Review
|
|
|
|
